Chamath Palihapitiya and Pablo Legorreta
January 18, 2022 10:37 AM ESTUpdated 02:26 PM
Financing

Bil­lion­aires Chamath Pal­i­hapi­tiya and Pablo Legor­re­ta hatch an $825M SPAC for cell ther­a­py biotech

John Carroll

Editor & Founder

Three years af­ter Roy­al­ty Phar­ma chief Pablo Legor­re­ta led a group of in­vestors to buy up a pair of biotechs and cre­ate a new start­up …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

FDA re­jects Stealth's rare dis­ease drug, but of­fers po­ten­tial for ac­cel­er­at­ed ap­proval

Up­dat­ed: Trump ad­min­is­tra­tion halts more than $750M in funds for Mod­er­na’s bird flu vac­cine

Pep­Gen ditch­es Duchenne pro­grams af­ter mid-stage fail, switch­es to pre­vi­ous­ly halt­ed mus­cle wast­ing ther­a­py

Ex­clu­sive: Move­ment dis­or­der biotech Vi­ma steps on­to scene with $60M

Oric locks down cash for Phase 3 prostate can­cer tri­al with ear­ly da­ta in hand

sponsored

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

A service from the Financial Times